About Armonica Technologies, Inc

Armonica Technologies derives its name from prolific innovator Benjamin Franklin’s favorite invention, The Glass Armonica. While our
technology is unrelated to the musical instrument, the same innovative spirit that drove its inventor serves as an inspiration to our team.

Board Of Directors/Executive Leadership

David Blivin, MBA

Managing Partner, Cottonwood Technology Funds

Cottonwood Technology Funds invests in seed/founding stage hard science technology companies across Photonics, Advanced Materials, Bio-Chemistry and Energy, Robotics and Health Sciences. Cottonwood is based in Santa Fe, NM and Enschede, The Netherlands and invests actively in both the Southwest US and Northern Europe. Prior to founding Cottonwood Technology Funds, David founded and served as Managing Director of Southeast Interactive where over a five-year period he successfully built the team that established the first and largest information technology-focused fund based in the Southeast. He holds a MBA from the Fuqua School of Business at Duke University.

David participates/participated on numerous other boards of directors including Skorpios, xF Technologies, Exagen, Respira, Bayotech, Lattice-X, OPNT, Eurekite, Sound Energy, The Pantry (nasdaq-PTRY), Opensite (sold to Siebel), Accipiter (sold to CMGI), Nitronex and Channelogics (sold to Scientific Atlanta).

Steven R. J. Brueck, Ph.D.

Chief Scientific Officer, Armonica Technologies

Steve is a Distinguished Professor of Electrical and Computer Engineering and of Physics, Emeritus at the University of New Mexico (UNM). Steve’s degrees are in Electrical Engineering (BS, Columbia University 1965, SM, MIT 1967 and PhD MIT 1971). Steve was a technical staff member at MIT Lincoln Laboratory from 1971 to 1985 when he joined UNM. He was appointed Director of the Center for High Technology Materials (CHTM) in 1987, stepping down as Director in 2013 and retiring from UNM as Distinguished Professor Emeritus in 2014. During his tenure, CHTM matured into an internationally respected research center in photonics, microelectronics and nanotechnology. Since its inception, CHTM has published over 2500 refereed journal articles, graduated over 460 MS and PhD students, been awarded over 207 US patents, and received over $208 M in research funding. He has been a member of the Board of Directors of LightPath Technologies, a global manufacturer, distributor and integrator of optical components and high-level assemblies since 2001.

Steve has published over 450 refereed papers, has presented over 250 invited papers and seminars, and holds 73 US patents. He has been active in professional societies chairing the Conference on Lasers and Electro-Optics (CLEO) in 2000, and the Electron, Ion, Photon Beam Nanofabrication and Applications (EIPBN) conference in 2008, and the Lithography Workshop in 2013. He has served on a number of National Academy Panels and Boards. He is a fellow of the IEEE, the OSA, the AAAS, and the National Academy of Inventors. In 2010 he was the first UNM Science and Technology Corporation Innovation fellow. In 2013 he was the inaugural recipient of the UNM Presidential Medal of Distinction for his contributions to the University of New Mexico.

Sally Corning, MBA

Co-Founder & Partner, Sun Mountain Capital

Sally is a Co-Founder and Partner at Sun Mountain Capital. Sally has extensive experience in evaluating investment opportunities, conducting due diligence, structuring transactions and raising equity and debt capital in both the public and private markets. She has worked in investment banking at Dean Witter Reynolds, Morgan Stanley and Credit Suisse. Prior to co-founding Sun Mountain Capital, Sally worked for 13 years in Credit Suisse’s Private Placement Group, where she led the evaluation of numerous companies and fund sponsors and structured, marketed and executed over 40 private transactions. Sally has an MBA from the Columbia University Graduate School of Business and a BSBA in Finance from Georgetown University.

Sally is a Board Member of Sun Mountain portfolio companies xF Technologies, BayoTech, and Risk Sense, Inc. Past investments include nanoMR (acquired by DNAe). Sally serves on the Limited Partner Advisory Committee for a number of private equity funds, is a Trustee for the Thornburg Investment Trust and is a member of the Board of Directors for the New Mexico Venture Capital Association.

Scott Goldman, MBA

East Region Associate Principal, Symphony Health

Scott has spent his career successfully driving change and innovation in the pharmaceutical, biotechnology, and life sciences industries. His leadership has unlocked value at both small start-up enterprises and large companies with revenues in excess of $20 billion. As a management consultant at PricewaterhouseCoopers (PwC) and other respected firms, Scott uncovered insights that led to the achievement of organizational KPIs, as well as successful technological change. Scott contributed to health industry thought leadership as part of PwC’s Health Research Institute team.

Prior to his consulting career, Scott held key strategy, sales, marketing and operation roles in the pharmaceutical and life science industry. At Eli Lilly, he developed national account marketing investment strategies, and delivered rapid sales increases in the areas under his supervision. At Janssen Pharmaceuticals, Scott made investment recommendations to senior management that substantially increased unit operational efficiency and effectiveness. Scott holds a Bachelor of Science in Applied Sciences in Engineering from Rutgers University, and a MBA from Goizueta Business School at Emory Univeristy.

Victor Esch, Ph.D.

President & Chief Executive Officer, Armonica Technologies

Victor Esch has over 20 years of experience successfully leading small companies, from very early stage through product introduction and company liquidity events, with a strong emphasis on technology and product development. Most recently, he was CEO of nanoMR, which introduced a highly sensitive sample prep technology for identifying causative pathogens in early stage sepsis. nanoMR was acquired by DNA Electronics (London, UK) in 2015. His first start-up experience was as Director of Research and Development at Indigo Medical, responsible for overseeing all product development for an interstitial laser treatment system for BPH. Indigo was acquired by Johnson & Johnson in 1996. He served as CTO of EndoVasix, a company that produced a laser based ischemic stroke treatment system. EndoVasix was acquired by W.L. Gore in 2006. He was a founder and the technology inventor at PowerVision, a medical device company that successfully developed an accommodating intraocular lens. PowerVision was sold to Alcon in 2019 for $285M. Victor has over 40 issued patents and his design innovations have been honored by R&D 100 and Photonics Circle of Excellence. He earned his Ph.D. in Optical Sciences from the University of Arizona.

Waneta Tuttle, MBA, Ph.D.

Fund Manager, Tramway Venture Partners

Waneta has 40 years of experience at the intersection of technology and health care. An entrepreneur, executive and experienced board member she brings an innovative spirit, grounded in practical understanding of health care. She holds a Ph.D. and an MBA and has started six companies. She served on the Board of Directors for NASDAQ traded MGI Pharma through its sale to Eisai Pharmaceuticals and she served for ten years (2007-2017) on the Board of Health Care Service Corporation, the nation’s fourth largest health insurer by enrollment. HCSC operates Blue Cross and Blue Shield of Illinois, Montana, New Mexico, Oklahoma and Texas. She also serves as a member of the Advisory Board to Tullis Health Investors of Florida and is a member of the corporation for the Charles Stark Draper Laboratory in Cambridge, Massachusetts.

Scientific Advisory Board

Charles R. Cantor, Ph.D.

Lead Scientific Advisor, Armonica Technologies

Charles is co-founder, and retired Chief Scientific Officer at SEQUENOM, Inc., the leading provider of noninvasive prenatal testing. He consults for a number of biotech companies, and is co-founder and executive director of Retrotope (USA), a clinical stage pharmaceutical company.

Charles was educated in chemistry at Columbia College (AB, 1963) and UC Berkeley (PhD, 1966). He became a full professor of chemistry at Columbia University at the age of 29. Charles has held academic and leadership positions at Columbia and several other distinguished American universities, but for the past 20 years he has focused his efforts in biotechnology companies. Charles is currently professor emeritus of Biomedical Engineering and of Pharmacology at Boston University. He is adjunct professor of Molecular Biology at the Scripps Institute for Research, distinguished adjunct professor of Physiology and Biophysics at UC Irvine, and adjunct professor at the Moscow institute of Physics and Technology.

Charles has been granted more than 60 US patents and, with Paul Schimmel, wrote a three-volume textbook on biophysical chemistry that has remained the standard in the field for more than 35 years. He has published more than 450 peer-reviewed articles, and is a member of the U.S. National Academy of Sciences and The National Academy of Inventors. His major scientific accomplishments include the development of pulsed field electrophoresis, immuno-PCR, affinity capture electrophoresis, the earliest uses of FRET to characterize distances in protein complexes and nucleic acids, the standard methods for assaying and purifying microtubule protein, various applications of nucleic acid mass spectrometry, and methods for noninvasive prenatal diagnostics. He is also considered to be one of the founders of the new field of synthetic biology.

Jeremy Edwards, Ph.D.

Professor of Molecular Genetics and Microbiology, University of New Mexico
Co-Director of The Comprehensive Cancer Center Bioinformatics, University of New Mexico

Jeremy’s research has focused on interfacing biology, bioinformatics, and engineering. He was the first person to take genome sequence information and develop predictive mathematical models of bacterial metabolism, which started a significant global effort culminating in multiple papers with about 1,000 citations. Stemming from an early interest in genomics technology, Jeremy chose to later work with Dr. George Church at Harvard Medical School in Boston for his post-doctoral studies. This work eventually developed into today’s NGS sequencing technology. Jeremy earned a B.S. in Mechanical Engineering from the University of Texas, Arlington, and a Ph.D. in Bioengineering from The Univerity of California, San Diego.

John Finan, MBA

Life Sciences Commercial Operations Leader, Baker Tilly Healthcare Consulting

John has spent his career in the Life Sciences industry and is an accomplished senior commercial executive with three decades driving corporate growth, expanding top-line revenue and improving EBITDA across the buy-side and sell-side in both corporate and professional services industries. His executive experience includes consulting within complex molecular diagnostics and biotechnology environments. John is currently with Baker Tilly Health Care Consulting, leading the Life Sciences Commercial Excellence Practice. John’s consulting experience also includes his boutique start-up firm, and a PwC consulting pedigree.

John’s expertise is derived from extensive experience as a pharmaceutical industry executive and through “strategy meets execution” benchmarking & advisory experience gained from his 12 years as a management consultant working with big, mid-sized and small pharmaceutical, medical device and clinical/molecular diagnostics companies. His management consulting history includes advising executive management clients in pharmaceutical and life sciences companies to address complex growth optimization challenges that include: new product launch planning including brand strategy, market access optimization, customer strategy and innovation, payer-driven market/product access and reimbursement, pricing, trade and multi-channel distribution strategy, sales effectiveness, management and operational process improvement.

Edgar A. Mendoza, Ph.D.

Chief Executive Officer, Redondo Optics Inc.

Ed leads the vision for Redondo Optics, including its technology and business strategy, venture capital fund raising, strategic alliances, intellectual property, team building, customer relations, and all R&D and product development activities. Ed was previously Founder and Chief Technology Officer of a venture funded company, OptiNetrics Inc., an advanced telecommunications company with a high-volume robotics manufacturing foundry for the production of silicon photonics transceivers based on his technology innovation patents. Prior to OptiNetrics, Ed worked both in academics as professor at Rutgers University, as well as in several government founded R&D corporations in California involved in the development of new technologies for transition to fast growth commercial sectors.

Ed received his Ph.D. from the City University of New York, and has 25 patents and over 150-publications in fields ranging from silicon photonics, fiber optics for sensors, remote sensing, nano-materials, Lab-on-Chip opto-fluidics, and diffractive and refractive optics. He has thirty years of experience working as a senior executive in strategic business planning and technological innovation in fast growth-based start-up companies focused on high growth technology markets such as life sciences, aerospace, oil & gas, renewable energy, defense and security.